JP2025501765A - 二官能性スルホンアミド化合物 - Google Patents
二官能性スルホンアミド化合物 Download PDFInfo
- Publication number
- JP2025501765A JP2025501765A JP2024538381A JP2024538381A JP2025501765A JP 2025501765 A JP2025501765 A JP 2025501765A JP 2024538381 A JP2024538381 A JP 2024538381A JP 2024538381 A JP2024538381 A JP 2024538381A JP 2025501765 A JP2025501765 A JP 2025501765A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- compound
- mmol
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904204A AU2021904204A0 (en) | 2021-12-22 | Bifunctional sulphonamide compounds | |
| AU2021904204 | 2021-12-22 | ||
| PCT/AU2022/051575 WO2023115149A1 (en) | 2021-12-22 | 2022-12-22 | Bifunctional sulphonamide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501765A true JP2025501765A (ja) | 2025-01-23 |
| JP2025501765A5 JP2025501765A5 (https=) | 2025-12-19 |
Family
ID=86900865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538381A Pending JP2025501765A (ja) | 2021-12-22 | 2022-12-22 | 二官能性スルホンアミド化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250074891A1 (https=) |
| EP (1) | EP4452966A4 (https=) |
| JP (1) | JP2025501765A (https=) |
| KR (1) | KR20240151737A (https=) |
| CN (1) | CN119013268A (https=) |
| AU (1) | AU2022420983A1 (https=) |
| CA (1) | CA3241593A1 (https=) |
| MX (1) | MX2024007883A (https=) |
| WO (1) | WO2023115149A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025096550A1 (en) * | 2023-10-31 | 2025-05-08 | Twine Therapeutics, Inc. | Methods of treating cardiomyopathy |
| WO2025155642A1 (en) * | 2024-01-21 | 2025-07-24 | The Regents Of The University Of California | Dcaf16-based covalent handle for the rational design of monovalent degraders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2948544A1 (en) * | 2014-05-15 | 2015-11-19 | Catalyst Therapeutics Pty Ltd | Methods for inhibiting necroptosis |
| CA2976121A1 (en) * | 2015-02-10 | 2016-08-18 | Catalyst Therapeutics Pty Ltd | Inhibitors of necroptosis |
| WO2018192416A1 (en) * | 2017-04-17 | 2018-10-25 | National Institute Of Biological Sciences, Beijing | Treating Male Senescence |
| CN114521196A (zh) * | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| DK4168401T3 (da) * | 2020-06-19 | 2026-04-13 | Anaxis Pharma Pty Ltd | Sulfonamidforbindelser |
-
2022
- 2022-12-22 MX MX2024007883A patent/MX2024007883A/es unknown
- 2022-12-22 EP EP22908911.5A patent/EP4452966A4/en active Pending
- 2022-12-22 JP JP2024538381A patent/JP2025501765A/ja active Pending
- 2022-12-22 KR KR1020247024222A patent/KR20240151737A/ko active Pending
- 2022-12-22 CN CN202280091905.7A patent/CN119013268A/zh active Pending
- 2022-12-22 CA CA3241593A patent/CA3241593A1/en active Pending
- 2022-12-22 AU AU2022420983A patent/AU2022420983A1/en active Pending
- 2022-12-22 WO PCT/AU2022/051575 patent/WO2023115149A1/en not_active Ceased
- 2022-12-22 US US18/722,003 patent/US20250074891A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250074891A1 (en) | 2025-03-06 |
| WO2023115149A1 (en) | 2023-06-29 |
| CA3241593A1 (en) | 2023-06-29 |
| CN119013268A (zh) | 2024-11-22 |
| AU2022420983A1 (en) | 2024-07-04 |
| EP4452966A4 (en) | 2025-12-17 |
| EP4452966A1 (en) | 2024-10-30 |
| KR20240151737A (ko) | 2024-10-18 |
| MX2024007883A (es) | 2024-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5524171B2 (ja) | キナーゼ阻害剤 | |
| JP7769648B2 (ja) | スルホンアミド化合物 | |
| AU2022349569A1 (en) | Pyridine derivative and use thereof | |
| CN112638373A (zh) | 细胞周期蛋白依赖性激酶抑制剂 | |
| WO2006080450A1 (ja) | Igf-1r阻害剤 | |
| TW201734015A (zh) | 1,5-萘啶衍生物與含此之melk抑制劑 | |
| JP2025501766A (ja) | 二官能性アリールスルホンアミド化合物 | |
| JP2025501765A (ja) | 二官能性スルホンアミド化合物 | |
| JP2024502178A (ja) | Sgk-1を阻害するためのピラゾロ[3,4-d]ピリミジン-6-イル-スルホンアミド誘導体 | |
| JPWO2019189555A1 (ja) | 複素環化合物 | |
| JP2020506172A (ja) | 化合物及び住血吸虫症の治療におけるそれらの使用 | |
| EP4452977A1 (en) | Arylsulphonamide compounds | |
| AU2021290652A1 (en) | Amido compounds | |
| KR20200032002A (ko) | 신규한 티아졸 유도체 및 이의 약학적으로 허용가능한 염 | |
| OA21863A (en) | Indazole based compounds and associated methods of use. | |
| HK40048972A (en) | Inhibitors of cyclin-dependent kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251211 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251211 |